Bet­ter than Eylea, as durable as gene ther­a­py? Per­cep­tive, Xon­toge­ny boost oph­thalmic star­tup's shot for best of all worlds

What’s the biggest break­through in the oph­thal­mol­o­gy space since Lu­cen­tis and Eylea?

No­var­tis’ Beovu, launched last No­vem­ber for wet age-re­lat­ed mac­u­lar de­gen­er­a­tion, has been ham­pered by safe­ty is­sues. Ko­di­ak Sci­ences sports $2.74 bil­lion on the promise of an an­ti­body biopoly­mer con­ju­gate that can be dosed every 16 weeks — re­duc­ing the treat­ment bur­den. Then there’s the line of gene ther­a­py play­ers from re­genxbio to Ad­verum, fol­low­ing in the foot­steps of Spark Ther­a­peu­tics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER